X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (167) 167
female (150) 150
oncology (120) 120
index medicus (118) 118
breast cancer (90) 90
middle aged (90) 90
breast neoplasms - drug therapy (77) 77
adult (75) 75
aged (75) 75
breast neoplasms - pathology (61) 61
cancer (50) 50
chemotherapy (46) 46
article (37) 37
antineoplastic combined chemotherapy protocols - therapeutic use (36) 36
chemotherapy, adjuvant (33) 33
survival (33) 33
breast neoplasms - mortality (30) 30
disease-free survival (30) 30
male (29) 29
therapy (29) 29
aged, 80 and over (28) 28
breast neoplasms - therapy (28) 28
treatment outcome (28) 28
care and treatment (26) 26
prognosis (25) 25
women (23) 23
breast neoplasms - metabolism (22) 22
clinical trials (21) 21
quality of life (20) 20
bone neoplasms - secondary (19) 19
research (19) 19
hematology, oncology and palliative medicine (18) 18
risk factors (18) 18
antineoplastic agents - therapeutic use (17) 17
antineoplastic combined chemotherapy protocols - adverse effects (17) 17
neoplasm staging (17) 17
paclitaxel (17) 17
postmenopausal women (17) 17
analysis (16) 16
breast neoplasms - genetics (16) 16
drug therapy (16) 16
medicine & public health (16) 16
medicine, general & internal (16) 16
original reports (16) 16
quality-of-life (16) 16
tamoxifen (16) 16
trial (16) 16
carcinoma (15) 15
cyclophosphamide - administration & dosage (15) 15
doxorubicin - administration & dosage (15) 15
follow-up studies (15) 15
health aspects (15) 15
randomized-trial (15) 15
risk (15) 15
trastuzumab (15) 15
united states (15) 15
diagnosis (14) 14
metastasis (14) 14
proportional hazards models (14) 14
randomized controlled trials as topic (14) 14
retrospective studies (14) 14
abridged index medicus (13) 13
breast neoplasms - diagnosis (13) 13
breast neoplasms - diagnostic imaging (13) 13
breast neoplasms - surgery (13) 13
breast-cancer (13) 13
combination (13) 13
patients (13) 13
zoledronic acid (13) 13
cyclophosphamide (12) 12
developing countries (12) 12
kaplan-meier estimate (12) 12
mortality (12) 12
neoplasm metastasis (12) 12
receptor, erbb-2 - metabolism (12) 12
usage (12) 12
young adult (12) 12
adjuvant treatment (11) 11
breast neoplasms - complications (11) 11
breast neoplasms - psychology (11) 11
cancer patients (11) 11
cancer therapies (11) 11
diphosphonates - therapeutic use (11) 11
double-blind (11) 11
doxorubicin (11) 11
follow-up (11) 11
mammography (11) 11
risk assessment (11) 11
endocrine therapy (10) 10
fluorouracil - administration & dosage (10) 10
neoadjuvant therapy (10) 10
recurrence (10) 10
bc5 (9) 9
bone metastases (9) 9
drug administration schedule (9) 9
immunohistochemistry (9) 9
obstetrics & gynecology (9) 9
paclitaxel - administration & dosage (9) 9
patient outcomes (9) 9
pet (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


ONCOLOGY-NEW YORK, ISSN 0890-9091, 10/2012, Volume 26, Issue 10, pp. 969 - 970
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 55 - 65
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9747, pp. 1186 - 1193
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2007, Volume 357, Issue 26, pp. 2666 - 2676
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 3, pp. 209 - 219
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 5, pp. 435 - 444
The combination of anastrozole and fulvestrant — which interfere with estrogen signaling by distinct mechanisms — increases progression-free and overall... 
PHASE-III TRIAL | MEDICINE, GENERAL & INTERNAL | ONCOLOGY-GROUP | TAMOXIFEN | DOUBLE-BLIND | RANDOMIZED-TRIAL | ENDOCRINE THERAPY | POSTMENOPAUSAL WOMEN | 1ST-LINE THERAPY | HORMONAL-THERAPY | FIRST-LINE THERAPY | Triazoles - administration & dosage | Triazoles - adverse effects | Estradiol - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Nitriles - administration & dosage | Aromatase Inhibitors - adverse effects | Neoplasm Metastasis | Aged, 80 and over | Estradiol - adverse effects | Postmenopause | Adult | Female | Aromatase Inhibitors - administration & dosage | Estradiol - administration & dosage | Kaplan-Meier Estimate | Breast Neoplasms - drug therapy | Cross-Over Studies | Disease-Free Survival | Estrogen Antagonists - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Estrogen Antagonists - adverse effects | Breast Neoplasms - mortality | Aged | Nitriles - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Breast cancer | Dosage and administration | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Fulvestrant | Statistical analysis | Anastrozole | Estrogen receptors | Tamoxifen | Cancer therapies | Survival | Patients | Post-menopause | Metastases | Chemotherapy | Womens health | Aromatase | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2015, Volume 372, Issue 10, pp. 923 - 932
Journal Article